AI Article Synopsis
- The ACIP 2016 guidelines recommend HPV vaccination for adolescents starting at ages 11-12, but current national rates are only 49.5%, indicating a need for improvement.
- An integrative literature review identified 201 studies, with 46 providing insights into barriers like provider recommendations and parental hesitancy, as well as effective strategies such as reminder systems.
- To improve vaccination rates, multi-method approaches combining strong provider recommendations and reminder systems are essential, as no single method has proven effective on its own.
Article Abstract
Problem: The updated Advisory Committee on Immunization Practices (ACIP) 2016 guidelines recommends vaccination for the human papillomavirus (HPV) for all adolescents starting at ages 11-12 years. The United States continues to fall short of the benchmarks set by Healthy People 2020. The national vaccination rates hover at 49.5%, creating much room for improvement in health care systems. The purpose of this literature review was to identify evidence-based interventions to implement for improved outcomes.
Eligibility Criteria: An integrative literature review was conducted using the CINAHL, EBSCO, Academic Search Complete, ProQuest and Medline databases. The search was limited to studies published in peer reviewed journals in the last 10 years.
Sample: Of the available studies, 201 met inclusion criteria with 46 studies meriting further review.
Results: Barriers to vaccination included missed opportunities due to lack of provider recommendation and awareness of current guidelines, and parental vaccination hesitancy. Effective strategies included reminder systems and strong provider recommendations.
Conclusions: No one method has been effective in maintaining increases in vaccination rates. Multi-method strategies demonstrate the highest rates of maintaining increases in HPV vaccination. Strong provider recommendations are a cornerstone to any multi-method intervention.
Implications: Providers and nurses need to shift conversations to strong recommendations for the HPV vaccination and include additional reminder systems, including protocols to meet Healthy People 2020 goals for HPV vaccination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pedn.2018.10.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population-level Impact of HPV Vaccination on the Incidence of Genital Warts in Sweden.
J Infect Dis
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, SE-17177 Stockholm, Sweden.
Background: Sweden introduced HPV vaccination in 2006, administered through opportunistic, subsidized, catch-up and school-based programs. Notably, genital warts (GW) are the first observable clinical outcome following infection by HPV-6/11, targeted by vaccination. We aim to gain knowledge of the incidence of GW in Sweden and evaluate its change throughout vaccination programs.
View Article and Find Full Text PDFMen's role in women's health: Engaging male partners in cervical cancer prevention efforts in low-to-middle-income countries.
Int J Gynecol Cancer
January 2025
Khulna University, Statistics Discipline, Khulna, Bangladesh.
Co-infection of human papillomavirus genotypes and Epstein-Barr virus in tumors of the oral cavity and oropharynx: a retrospective study in Northeastern Mexico.
IJID Reg
March 2025
Laboratorio de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, México.
Objectives: This study aimed to determine the prevalence and genotyping of human papillomavirus (HPV) and to assess co-infection with Epstein-Barr virus (EBV) in oral cavity and oropharyngeal cancers (OC and OPC) specimens from patients at a tertiary care hospital in Northeastern Mexico.
Methods: Formalin-fixed and paraffin-embedded tumor specimens from 41 patients with OC and OPC were evaluated. HPV detection and genotyping were performed using the Ampliquality HPV-Type Express kit.
Risk of residual/recurrent cervical diseases in HPV-positive women post-conization depends on HPV integration status.
Infect Agent Cancer
January 2025
College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, 350001, China.
Background: It is crucial to identify post-operative patients with HPV infection who are at high risk for residual/recurrent disease. This study aimed to evaluate the association between HPV integration and clinical outcomes in HPV-positive women after cervical conization, as well as to identify HPV integration breakpoints.
Methods: This retrospective study analyzed data of 791 women who underwent cervical conization for cervical intraepithelial neoplasia grades 2-3 (CIN2-3) between September 2019 and September 2023, sourced from the Fujian and Hubei cervical lesion screening cohorts.
Prevalence of non-vaccine high-risk HPV cervical infections in vaccinated women: a systematic review and meta-analysis.
BMC Infect Dis
January 2025
Programa de Pós-graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
Background: Human Papillomavirus (HPV) is the most common sexually transmitted lower genital tract infection worldwide and the main etiological factor of cervical cancer (CC). Since 2006, vaccines have been implemented to reduce CC-related morbidity and mortality. This systematic review and meta-analysis aimed to evaluate the prevalence of cervical infections by non-vaccine high-risk HPV (HR-HPV) types in women vaccinated against types 16 and 18.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!